CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumonia e and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3
Metadata
Show full item recordAuthor
Cañada-García, Javier E; Moure, Zaira; Sola-Campoy, Pedro J; Delgado-Valverde, Mercedes; Cano, María E; Gijón, Desirèe; González, Mónica; Gracia-Ahufinger, Irene; Larrosa, Nieves; Mulet, Xavier; Pitart, Cristina; Rivera, Alba; Bou, Germán; Calvo, Jorge; Cantón, Rafael; González-López, Juan José; Martínez-Martínez, Luis; Navarro, Ferran; Oliver, Antonio; Palacios-Baena, Zaira R; Pascual, Álvaro; Ruiz-Carrascoso, Guillermo; Vila, Jordi; Aracil, Belén; Pérez-Vázquez, María; Oteo-Iglesias, Jesús; GEMARA/GEIRAS-SEIMC/REIPI CARB-ES-19 Study GroupEditorial
Frontiers Media
Materia
CARB-ES-19 study Carbapenemases Whole genome sequencing Klebsiella pneumoniae High-risk clones
Date
2022-06Referencia bibliográfica
Cañada-García et al. CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3. Frontiers in Microbiology vol. 13 - 2022. https://doi.org/10.3389/fmicb.2022.918362
Sponsorship
Instituto de Salud Carlos III (numbers PI18CIII/00030 and PI21CIII/00039); Ministerio de Economía y Competitividad (RD16CIII/0004/0002, RD16/0016/0001, RD16/0016/0003, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0008, RD16/0016/0010, RD16/0016/0011); European Development Regional Fund, Operative Program Intelligent Growth 2014– 2020; Consorcio Centro de Investigación Biomédica en Red (CB21/13/00095, CB21/13/00012, CB21/13/00049, CB21/13/00054, CB21/13/00055, CB21/13/00068, CB21/13/00081, CB21/13/00084, CB21/13/00099); Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEUAbstract
Objectives: CARB-ES-19 is a comprehensive, multicenter, nationwide study integrating whole-genome sequencing (WGS) in the surveillance of carbapenemase-producing K. pneumoniae (CP-Kpn) and E. coli (CP-Eco) to determine their incidence, geographical distribution, phylogeny, and resistance mechanisms in Spain.
Methods: In total, 71 hospitals, representing all 50 Spanish provinces, collected the first 10 isolates per hospital (February to May 2019); CPE isolates were first identified according to EUCAST (meropenem MIC > 0.12 mg/L with immunochromatography, colorimetric tests, carbapenem inactivation, or carbapenem hydrolysis with MALDI-TOF). Prevalence and incidence were calculated according to population denominators. Antibiotic susceptibility testing was performed using the microdilution method (EUCAST). All 403 isolates collected were sequenced for high-resolution single-nucleotide polymorphism (SNP) typing, core genome multilocus sequence typing (cgMLST), and resistome analysis.
Results: In total, 377 (93.5%) CP-Kpn and 26 (6.5%) CP-Eco isolates were collected from 62 (87.3%) hospitals in 46 (92%) provinces. CP-Kpn was more prevalent in the blood (5.8%, 50/853) than in the urine (1.4%, 201/14,464). The cumulative incidence for both CP-Kpn and CP-Eco was 0.05 per 100 admitted patients. The main carbapenemase genes identified in CP-Kpn were bla OXA-48 (263/377), bla KPC-3 (62/377), bla VIM-1 (28/377), and bla NDM-1 (12/377). All isolates were susceptible to at least two antibiotics. Interregional dissemination of eight high-risk CP-Kpn clones was detected, mainly ST307/OXA-48 (16.4%), ST11/OXA-48 (16.4%), and ST512-ST258/KPC (13.8%). ST512/KPC and ST15/OXA-48 were the most frequent bacteremia-causative clones. The average number of acquired resistance genes was higher in CP-Kpn (7.9) than in CP-Eco (5.5).
Conclusion: This study serves as a first step toward WGS integration in the surveillance of carbapenemase-producing Enterobacterales in Spain. We detected important epidemiological changes, including increased CP-Kpn and CP-Eco prevalence and incidence compared to previous studies, wide interregional dissemination, and increased dissemination of high-risk clones, such as ST307/OXA-48 and ST512/KPC-3.